ExodusPoint Capital Management 增持了陷入困境但前景光明的 Liquidia Corporation 的股份。 ExodusPoint Capital Management increased its stake in struggling but promising Liquidia Corporation.

通过购买31027股,总共60770股,ExodusPoint Capital Management LP增加了其在生物制药公司Liquidia Corporation的股权. ExodusPoint Capital Management LP increased its stake in Liquidia Corporation, a biopharmaceutical company, by buying 31,027 shares, totaling 60,770 shares. 利基迪亚最近的财务报告显示收益负面, 但分析师的评级是"买入"目标价为26.63美元. Liquidia's recent financials show negative returns, but analysts have a "Buy" rating with a target price of $26.63. 该公司的市场上限为11.5亿美元,重点是为未得到满足的医疗需求制定治疗办法。 The company’s market cap is $1.15 billion, and it focuses on developing treatments for unmet medical needs.